Iatrogenic Second Tumors

  • Pietro Lombari
  • Loredana Vecchione
  • Antonio Farella
  • Sebastiano Grassia
  • Fernando De Vita
  • Giuseppe Catalano
  • Marco Salvatore
  • Andrea Renda
Part of the Updates in Surgery book series (UPDATESSURG)


The recent introduction of new chemotherapeutic and radiotherapeutic schemes into clinical practice has led to the improvement in the overall survival of cancer patients. Hodgkin’s disease, testicular cancer, and pediatric malignancies are the pathologies with the highest survival rate; improved cure rates have also been achieved for breast cancer, ovarian cancer, and non-Hodgkin’s lymphoma. However, the long-term survival and/or recovery conferred by these treatments paradoxically expose cancer patients to a higher risk of important longterm complications, the most serious of which is the development of a second tumor.


Rectal Cancer Acute Myeloid Leukemia Natl Cancer Inst Linear Energy Transfer Antineoplastic Drug 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Greene MH (1992) Is cisplatin a human carcinogen? J Natl Cancer Inst 84:306PubMedCrossRefGoogle Scholar
  2. 2.
    IARC (1987) Overall evaluations of carcinogenicity: an updating of IARC monographs volumes 1 to 42. IARC Monogr Eval Carcinog Risks Hum Suppl 7:1Google Scholar
  3. 3.
    Cheson BD, Vena DA, Barrett J, Freidlin B (1999) Second malignancies as a consequence of nucleoside analog therapy for chronic lymphoid leukemia. J Clin Oncol 17(8):2454PubMedGoogle Scholar
  4. 4.
    Travis LB, Curtis RE, Grimelius B et al (1995) Bladder and kidney cancer following cyclophosphamide therapy for non-Hodgkin’s lymphoma. J Natl Cancer Inst 87:524PubMedCrossRefGoogle Scholar
  5. 5.
    Felix CA (1999) Chemotherapy-related second cancers. In: Neugut AI, Meadows AT, Robinson E (eds) Multiple primary cancers. Lippincott Williams & Wilkins, Philadelphia, p 137Google Scholar
  6. 6.
    Ben-Yehuda D, Krichevsky S, Caspi O et al (1996) Microsatellite instability and p53 mutations in therapy-related leukemia suggest mutator phenotype. Blood 88(11):4296PubMedGoogle Scholar
  7. 7.
    Smith MA, McCaffrey RP, Karp JE (1996) The secondary leukemia: challenges and research directions”. J Natl Cancer Inst 88(7):407PubMedCrossRefGoogle Scholar
  8. 8.
    Davies Stella M (1995) Mechanisms of cytotoxicity and leukemogenesis: topoisomerase II inhibitors and alkylating agents. In ASCO Educational Book, American Society of Clinical Oncology Educational Symposia. 31st annual meeting; May 20-23, 1995, Los Angeles, p 204Google Scholar
  9. 9.
    Pedersen-Bjergaard J, Rowley JD (1994) The balanced and the unbalanced chromosome aberrations of acute myeloid leukemia may develop in different ways and may contribute differently to malignant transformation. Blood 83:2780PubMedGoogle Scholar
  10. 10.
    Smith MA, Rubinstein L, Ungerleider RS (1994) Therapy-related acute myeloid leukemia following treatment with epipodophyllotoxins: estimating the risks. Med Pediatric Oncol 23:86CrossRefGoogle Scholar
  11. 11.
    Levine EG, Bloomfield CD (1992) Leukemias and myelodysplastic syndromes secondary to drug, radiation, and environmental exposure. Semin Oncol 19:47PubMedGoogle Scholar
  12. 12.
    Pedersen-Bjergaard J, Philip P, Larsen G, Byrsting K (1990) Chromosome aberrations and prognostic factors in therapy-related myelodysplasia and acute nonlymphocytic leukemia. Blood 76:1083PubMedGoogle Scholar
  13. 13.
    Van Leeuwen FE, Chorus AM, van der Belt-Dusebout AW et al (1994) Leukemia risk following Hodgkin’s disease: relation to cumulative dose of alkylating agents, treatment with teniposide combinations, number of episodes of chemotherapy, and bone marrow damage. J Clin Oncol 12:1063PubMedGoogle Scholar
  14. 14.
    Pedersen-Bjergaard J, Pedersen M, Roulston D, Philip P (1995) Different genetic pathways in leukemogenesis for patients presenting with therapy-related myelodysplasia and therapyrelated acute myeloid leukemia. Blood 86(9):3542PubMedGoogle Scholar
  15. 15.
    Pedersen-Bjergaard J, Philip P (1991) Balanced translocations involving chromosome bands 1 1q23 and 21q22 and highly characteristic of myelodisplasia and leukemia following therapy with cytotatic agents targeting at DNA-topoisomerase II (Letter). Blood 78:1147PubMedGoogle Scholar
  16. 16.
    Valagussa PA, Bonadonna G (1995) Carcinogenic effects of cancer treatment. In: Peckham M, Pinedo H, Veronesi U (eds) Oxford textbook of oncology. Oxford University Press, Oxford, p 2348Google Scholar
  17. 17.
    Kaldor JM, Day NE, Klarke EA et al (1990) Leukemia following Hodgkin’s disease (see comments). N Engl J Med 322:7PubMedGoogle Scholar
  18. 18.
    Park S, Brice P, Noguerra ME et al (2000) Myelodysplasias and leukemias after autologous stem cell transplantation for lymphoid malignancies. Bone Marrow Transplant 26(3):321PubMedCrossRefGoogle Scholar
  19. 19.
    Metayer C, Curtis RE, Vose J et al (2003) Myelodisplastic syndrome and acute myeloid leucemia after autotransplantation for lymphoma: a multicenter case control study. Blood 101(5):2015PubMedCrossRefGoogle Scholar
  20. 20.
    Bonadonna G, Valagussa G (2003) Tumori iatrogeni. In: Bonadonna G, Valagussa G, Robustelli della Cuna G (eds) Medicina Oncologica, VII edizione. Elsevier Masson, Bologna, pp 1663–1680Google Scholar
  21. 21.
    Van Leeuwen FE, Klokman WJ, Stovall M et al (2003) Roles of radiation dose, chemotherapy and hormonal factors in breast cancer following Hodgkin’s disease. J Natl Cancer Inst 95(13):971PubMedGoogle Scholar
  22. 22.
    van Leeuwen FE, Travis LB (2005) Second cancers. In: De Vita VT, Hellman S, Rosenberg SA (eds) Cancer: principles and practice of oncology, 7th edn. Lippincott Williams & Wilkins, Philadelphia, pp 2575–2600Google Scholar
  23. 23.
    Bernstein L, Deapen D, Cerhan JR et al (1999) Tamoxifen therapy for breast cancer and endometrial cancer risk. J Natl Cancer Inst 91(19): 1654PubMedCrossRefGoogle Scholar
  24. 24.
    Lend CE, Tokunaga M, Koyama K et al (2003) Incidence of female breast cancer among atomic bomb survivors, Hiroshima-Nagasaki 1950-1990. Radiat Res 160:707–717CrossRefGoogle Scholar
  25. 25.
    Thompson DE, Mabuchi K, Ron E et al (1994) Cancer incidence in atomic bomb survivors. Part II: Solid tumors, 1958-1987. Radiat Res 137(2 Suppl):S17–S67PubMedCrossRefGoogle Scholar
  26. 26.
    Sachs RK et al (2005) Solid tumor risks after high doses of ionizing radiation. Proc Natl Acad Sci USA 102(37): 13040–13045PubMedCrossRefGoogle Scholar
  27. 27.
    Palmer JP et al (1956) Pelvic carcinoma following irradiation for benign gynecological diseases. Am J Obstet Gynecol 72:497–505PubMedGoogle Scholar
  28. 28.
    Bernstein M et al (1991) Radiation-induced tumors of the nervous system In: Gutin Ph et al (eds) Radiation injury to the nervous system. Raven, New York, pp 455–472Google Scholar
  29. 29.
    Perez CA, Brady LW (1998) Principles and practice of radiation oncology. JB Lippincott, PhiladelphiaGoogle Scholar
  30. 30.
    Orecchia R, Lucignani G, Tosi G (2001) Elementi di radiobiologia clinica e radioprotezione. Archimedica, TurinGoogle Scholar
  31. 31.
    Baxter NN et al (2005) Increased risk of rectal cancer after prostate radiation: a populationbased study. Gastroenterology 128:819–824PubMedCrossRefGoogle Scholar
  32. 32.
    Birgisson H et al (2005) Occurrence of second cancers in patients treated with radiotherapy for rectal cancer. J Clin Oncol 23:25Google Scholar
  33. 33.
    Travis LB et al (1997) Risk of second malignant neoplasm among long-term survivors of testicular cancer. J Natl Cancer 89:1429–1439CrossRefGoogle Scholar
  34. 34.
    Valagussa P (1993) Second neoplasm following treatment of H.D. Current Opinion Oncol 5:805–811CrossRefGoogle Scholar
  35. 35.
    Kennedy BJ (1998) The National Cancer data base report on Hodgkin’s disease. Cancer 83(5):1041–1047PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Italia 2009

Authors and Affiliations

  • Pietro Lombari
    • 1
  • Loredana Vecchione
    • 2
  • Antonio Farella
    • 3
  • Sebastiano Grassia
    • 1
  • Fernando De Vita
    • 2
  • Giuseppe Catalano
    • 2
  • Marco Salvatore
    • 3
  • Andrea Renda
    • 1
  1. 1.Surgical, Anesthesiology-rianimative and Emergency Sciences DepartmentFederico II UniversityNaplesItaly
  2. 2.Medical Oncology, Department of Clinical and Experimental Medicine “F. Magrassi - A. Lanzara”Second University of NaplesNaplesItaly
  3. 3.Department of Biomorfological and Functional Sciences, Unit of Diagnostic Imaging and RadiotherapyFederico II UniversityNaplesItaly

Personalised recommendations